| |
| |
|
| Insider
Information: |
Geraghty James A |
| Relationship: |
|
| City: |
Framingham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
311,097 |
|
|
Indirect Shares
|
138 |
|
|
| Direct
Value |
$689,137 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
311,235 |
|
|
| Total
Value |
$689,137 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
GTC Biotherapeutics Inc |
GTCB |
Director |
2009-12-31 |
19,025 |
2009-12-31 |
138 |
Premium* |
|
|
Genzyme Corp |
GENZ |
Senior Vice President |
2011-04-04 |
0 |
2011-04-04 |
0 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
2021-01-04 |
104,770 |
2013-08-19 |
0 |
Premium* |
|
|
Juniper Pharmaceuticals Inc |
JNP |
Director |
2018-08-14 |
0 |
2015-05-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
Director |
2018-09-10 |
76,588 |
|
0 |
Premium* |
|
|
Pieris Pharmaceuticals, Inc. |
PIRS |
|
2018-05-15 |
20,000 |
2017-08-17 |
0 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
Director |
2021-06-28 |
90,714 |
|
0 |
Premium* |
|
|
Orchard Therapeutics Plc |
ORTX |
|
2024-01-24 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACGN |
Aceragen, Inc |
Director |
– • – |
2020-07-01 |
4 |
A |
$1.79 |
$19,500 |
D/D |
10,894 |
91,253 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2020-10-01 |
4 |
A |
$2.25 |
$19,499 |
D/D |
8,666 |
99,919 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2021-01-04 |
4 |
A |
$4.02 |
$19,501 |
D/D |
4,851 |
104,770 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
Director |
– • – |
2021-06-28 |
4 |
B |
$9.16 |
$91,600 |
D/D |
10,000 |
90,714 |
2.39 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2009-11-06 |
4 |
OE |
$32.52 |
$1,199,175 |
D/D |
36,875 |
39,226 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2009-11-06 |
4 |
S |
$52.07 |
$1,920,081 |
D/D |
(36,875) |
2,351 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2010-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
7,685 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2010-05-25 |
4 |
S |
$45.59 |
$106,179 |
D/D |
(2,329) |
5,356 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2010-06-11 |
4 |
S |
$48.81 |
$48,810 |
D/D |
(1,000) |
4,356 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2011-04-04 |
4 |
D |
$74.00 |
$8,288 |
I/I |
(112) |
0 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2011-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,750 |
14,595 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2011-04-04 |
4 |
D |
$74.00 |
$358,530 |
D/D |
(4,845) |
9,750 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice President |
• – – |
2011-04-04 |
4 |
D |
$74.00 |
$721,500 |
D/D |
(9,750) |
0 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Senior Vice PresidentOfficer |
• – – |
2008-05-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,025 |
|
- |
|
| GENZ |
Genzyme Corp |
Senior Vice PresidentOfficer |
• – – |
2008-05-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
112 |
|
- |
|
65 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
